World Lung 2024 – Boehringer and Bayer battle over a lung cancer niche
Spectrum’s poziotinib failed in HER2 exon 20 lung cancer, but that isn’t stopping Boehringer and Bayer.
World Lung 2024 – ArriVent looks for lung cancer white space
The group is going beyond EGFR exon 20 insertions, but still has work to do to justify its valuation.
An alpha turnaround for Relay
The fortunes of RLY-2608 reverse, and a pivotal study will follow.
World Lung 2024 – picking apart the Harmoni-2 win
Akeso’s data look impressive, but perhaps not impressive enough to sustain Summit’s valuation.
World Lung 2024 – backing for ifinatamab’s pivotal move
The mid-stage Ideate-Lung01 study bears out ifinatamab-dxd’s efficacy in small-cell lung cancer.
The pieces of Vor’s puzzle start to come together
The depressed company could use Mylotarg as a stepping stone in AML.
Interim miss slows IO Biotech
An accelerated approval looks off the table, as the group’s first-line melanoma trial continues.
